105 research outputs found
Bilateral Industrial Symbiosis. An assessment of its potential in New South Wales to deal sustainably with manufacturing waste
Manufacturing takes place in NSW on sites that are dispersed throughout the state. They may be isolated, remote from one another and hence from likely users of their waste. This scenario is not conducive to industrial symbiosis which is conventionally understood to be a network of organisations in close geographic proximity that share resources, cascade energy and use each other’s waste. Regulations governing the disposal of waste are stringent and associated costs are significant, largely due to the highest landfill levies anywhere in Australia. The state government’s strategy is to increase levies to a level that ‘induces’ generators of waste to find alternatives to landfill. Responding to these challenges will necessitate a fundamental change in the approach to dealing with waste. The way in which manufactures might accomplish the change sustainably and systematically is the underlying issue addressed in this thesis. The concept of physical bilateral symbiosis, specifically an arrangement between a generator of waste and its user, has been developed to suit geographic conditions in NSW. However, an attempt to establish trials of its autogenous form was unsuccessful. Nevertheless, results of the attempt indicated that broader issues should be investigated: managers’ perceptions of waste disposal, their willingness and their capacity to meet the challenges imposed by government; collectively, what I have called a generator’s internal infrastructure. These issues, in turn, led to an investigation of how third parties, that is, the external infrastructure, might be able to facilitate bilateral symbiosis. The principal findings are that while some generators may develop uses for their waste others will simply not be able to do so. There is, in practice, no external infrastructure capable of facilitating systematic, bilateral symbiosis on behalf of a generator. Furthermore, government action, particularly in relation to policy on funding, is neither appropriate nor adequate for sustainable development in relation to waste. The overall conclusion is that much could be done by the private sector to increase the use of waste, if government policy were to support the effort. However, that support is expected to be very difficult to achieve, even in the form of appropriate legislation in NSW, let alone coordinated among the various jurisdictions in Australia. In regard to what actually happens in practice, the current scenario in general is unlikely to change significantly within the foreseeable future
Recognition of genetic predisposition in pediatric cancer patients: An easy-to-use selection tool
Genetic predisposition for childhood cancer is under diagnosed. Identifying these patients may lead to therapy adjustments in case of syndrome-related increased toxicity or resistant disease and syndrome-specific screening programs may lead to early detection of a further independent malignancy. Cancer surveillance might also be warranted for affected relatives and detection of a genetic mutation can allow for reproductive counseling.Here we present an easy-to-use selection tool, based on a systematic review of pediatric cancer predisposing syndromes, to identify patients who may benefit from genetic counseling. The selection tool involves five questions concerning family history, the type of malignancy, multiple primary malignancies, specific features and excessive toxicity, which results in the selection of those patients that may benefit from referral to a clinical geneticist
Communicating with young patients in pediatric oncology consultations:A vignette study on patients', parents', and survivors' communication preferences
Multi-Band Limiter Value to Production Chain and Its Processing Limitation
Architecture & Allied Art
Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view
Introduction: In several studies, the chimeric antigen receptor T-cell therapy tisagenlecleucel demonstrated encouraging rates of remission and lasting survival benefits in pediatric patients with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL). We assessed the cost-effectiveness of tisagenlecleucel (list price: 320Â 000 EUR) among these patients when compared to clofarabine monotherapy (Clo-M), clofarabine combination therapy (Clo-C), and blinatumomab (Blina) from both a healthcare and a societal perspective. We also assessed future medical and future non-medical consumption costs. Methods: A three-state partitioned survival model was used to simulate a cohort of pediatric patients (12Â years of age) through different disease states until the end of life (lifetime horizon). Relevant outcomes were life years, quality-adjusted life years (QALYs), healthcare costs, societal costs, and the incremental cost-effectiveness ratio (ICER). Uncertainty was explored through deterministic and probabilistic sensitivity analyses as well as through several scenario analyzes. Results: Total discounted costs for tisagenlecleucel were 552Â 679 EUR from a societal perspective, which was much higher than the total discounted costs from a healthcare perspective (ie, 409Â 563 EUR). Total discounted societal costs for the comparator regimens ranged between 160Â 803 EUR for Clo-M and 267Â 259 EUR for Blina. Highest QALYs were estimated for tisagenlecleucel (11.26), followed by Blina (2.25), Clo-C (1.70) and Clo-M (0.74). Discounted societal ICERs of tisagenlecleucel ranged between 31Â 682 EUR/QALY for Blina and 37Â 531 EUR/QALY for Clo-C and were considered cost-effective with a willingness-to-pay (WTP) threshold of 80Â 000 EUR/QALY. None of the scenarios exceeded this threshold, and more than 98% of the iterations in the probabilistic sensitivity analysis were cost-effective. Discussion: At the current price and WTP threshold, tisagenlecleucel is cost-effective from both a healthcare and a societal perspective. Nevertheless, long-term effectiveness data are needed to validate the several assumptions that were necessary for this model
Characterisation of puroindoline genes in wild tetraploid and hexaploid wheats (Triticum araraticum; T. timopheevii and T. zhukovskyi)
Treatment with cisplatin-containing chemotherapy regimens causes hearing loss in 40-60% of cancer patients. It has been suggested that genetic variants in the genes encoding thiopurine S-methyltransferase (TPMT) and catechol O-methyltransferase (COMT) can predict the development of cisplatin-induced ototoxicity and may explain interindividual variability in sensitivity to cisplatin-induced hearing loss. Two recently published studies however, sought to validate these findings and showed inconsistent results. The aim of this study was to evaluate the role of polymorphisms in the TPMT and COMT genes in cisplatin-induced ototoxicity. Therefore we investigated two independent cohorts of 110 Dutch and 38 Spanish patients with osteosarcoma and performed a meta-analysis including all previously published studies resulting in a total population of 664 patients with cancer. With this largest meta-analysis performed to date, we show that the influence of TPMT and COMT on the development of cisplatin-induced hearing loss may be less important than previously suggested
Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations
Genomic studies of pediatric acute lymphoblastic leukemia (ALL) have shown remarkable heterogeneity in initial diagnosis, with multiple (sub)clones harboring lesions in relapse-associated genes. However, the clinical relevance of these subclonal alterations remains unclear. We assessed the clinical relevance and prognostic value of subclonal alterations in the relapse-associated genes IKZF1, CREBBP, KRAS, NRAS, PTPN11, TP53, NT5C2, and WHSC1 in 503 ALL cases. Using molecular inversion probe sequencing and breakpoint-spanning polymerase chain reaction analysis we reliably detected alterations with an allele frequency below 1%. We identified 660 genomic alterations in 285 diagnostic samples of which 495 (75%) were subclonal. RAS pathway mutations were common, particularly in minor subclones, and comparisons between RAS hotspot mutations revealed differences in their capacity to drive clonal expansion in ALL. We did not find an association of subclonal alterations with unfavorable outcome. Particularly for IKZF1, an established prognostic marker in ALL, all clonal but none of the subclonal alterations were preserved at relapse. We conclude that, for the genes tested, there is no basis to consider subclonal alterations detected at diagnosis for risk group stratification of ALL treatment.Development and application of statistical models for medical scientific researc
Germline MBD4-deficiency causes a multi-tumor predisposition syndrome
We report an autosomal recessive, multi-organ tumor predisposition syndrome, caused by bi-allelic loss-of-function germline variants in the base excision repair (BER) gene MBD4. We identified five individuals with bi-allelic MBD4 variants within four families and these individuals had a personal and/or family history of adenomatous colorectal polyposis, acute myeloid leukemia, and uveal melanoma. MBD4 encodes a glycosylase involved in repair of G:T mismatches resulting from deamination of 5′-methylcytosine. The colorectal adenomas from MBD4-deficient individuals showed a mutator phenotype attributable to mutational signature SBS1, consistent with the function of MBD4. MBD4-deficient polyps harbored somatic mutations in similar driver genes to sporadic colorectal tumors, although AMER1 mutations were more common and KRAS mutations less frequent. Our findings expand the role of BER deficiencies in tumor predisposition. Inclusion of MBD4 in genetic testing for polyposis and multi-tumor phenotypes is warranted to improve disease management
Kinderoncologie : meer dan pittige pilletjes
Contains fulltext :
18818_kind.pdf (publisher's version ) (Open Access)21 p
Nieuwe genomische markers voor diagnostiek en behandeling van voorloper-b-cel acute lymfatische leukemie bij kinderen.
Contains fulltext :
89729.pdf (publisher's version ) (Open Access
- …